Biotech Developments to Watch
#sethyakatan #katanassociates Antibiotics, Gut Bacteria and Liver Disease This week there was a pretty interesting development which was...
top of page
Search
Sirnaomics Closed Series C1 Financing of $25 Million and Expands Clinical Programs of Anti-Fibrosis
GAITHERSBURG, MD, June 6, 2018 -- Sirnaomics, Inc. (www.sirnaomics.com), a leading biopharmaceutical company in development of RNAi...
BIO USA
Dr. Tara Smith and Seth Yakatan will be in Boston June 4-7, 2018 for Bio USA. Reach us through the Bio partnering portal or contact us...
GFPD Conference
Dr. Tara Smith will be attending the Global Foundation for Peroxisomal Disorders Scientific Conference June 1 & 2, 2018, in Washington,...
FitLife Brands Announces First Quarter 2018 Results
FitLife Brands, Inc. ("FitLife") (OTCPink: FTLF), an international provider of innovative and proprietary nutritional supplements for...
Dr. Steven Long Joins Sirnaomics Senior Management Team as Head of China Clinical Studies
Gaithersburg, MD, May 3rd, 2018 -- Sirnaomics, Inc. (www.sirnaomics.com), a leading biopharmaceutical company in discovery and...
Investor Update
Dear Shareholder, We are very pleased to be providing this Investor Update, which details the activities of recent months and plans for...
FitLife Brands Announces 2017 Results
FitLife Brands, Inc. ("FitLife") (OTC:PINK - FTLF), an international provider of innovative and proprietary nutritional supplements for...
NEUROTECH
UPDATE! MLD is pleased to announce it has been selected as one of eight companies to present in the Emerging Companies Showcase at...
Leading ovarian cancer expert Dr Andrew Stephens appointed to Invion’s advisory board
Dr Andrew Stephens from Hudson Institute of Medical Research has accepted an appointment on Invion’s advisory board Dr Stephens is one of...
Invion secures research alliance with Hudson Institute of Medical Research
Hudson Institute is a leading Australian biomedical research institute recognised internationally for delivering better health through...
Kalytera Initiates Program
Kalytera Initiates Program to Develop a Novel Cannabinoid-Based Compound for Treatment of Acute and Chronic Pain Kalytera Therapeutics,...
Change of registered office and principal place of business
INVION LIMITED: CHANGE OF REGISTERED OFFICE AND PRINCIPAL PLACE OF BUSINESS Invion Limited (ASX:IVX) wishes to advise that, effective 16...
MLD presenting at Digestive Diseases Week 2018
Dr. Shawn Ritchie, on behalf of MLD and our collaborators at Rush University, will be presenting at DDW in Washington DC on June 3, 2018....
Invion announces Underwritten Rights Issue
NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES Invion announces fully underwritten non-renounceable rights issue to raise...
Kalytera Announces Grant of Stock Options
Kalytera Therapeutics, Inc. (TSX VENTURE:KALY) (KALTF) (the “Company” or “Kalytera”) today announced that it has granted stock options on...
Kalytera Announces Issuance
Kalytera Announces Issuance of Shares under Services Agreement with The Salzman Group of Israel Kalytera Therapeutics, Inc. (KALY.V)...
TPD Forensic Lab Looks Doing More With Lean Six Sigma and Sorenson Forensics
“Budgets are not really being increased we are not really getting a lot of money so we have to figure out ways to increase efficiency and...
Kalytera Announces Settlement of Debt Transactions
Kalytera Announces Settlement of Debt Transactions Approval of Shares for Services and Settlement of Debt Transaction with The Salzman...
Appendix 4C – December 2017 Quarter
The Manager Company Announcements Office ASX Limited, 20 Bridge St, SYDNEY NSW 2000 Dear Sir APPENDIX 4C Invion Limited (ASX:IVX) is...
bottom of page